MetaStat Inc
MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the … Read more
MetaStat Inc (MTST) - Net Assets
Latest net assets as of February 2018: $-1.55 Million USD
Based on the latest financial reports, MetaStat Inc (MTST) has net assets worth $-1.55 Million USD as of February 2018.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($729.63K) and total liabilities ($2.28 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.55 Million |
| % of Total Assets | -212.29% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 790.29 |
MetaStat Inc - Net Assets Trend (2008–2018)
This chart illustrates how MetaStat Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MetaStat Inc (2008–2018)
The table below shows the annual net assets of MetaStat Inc from 2008 to 2018.
| Year | Net Assets | Change |
|---|---|---|
| 2018-02-28 | $-1.55 Million | +44.59% |
| 2017-02-28 | $-2.80 Million | -57.94% |
| 2016-02-29 | $-1.77 Million | -829.36% |
| 2015-02-28 | $242.65K | +111.66% |
| 2014-02-28 | $-2.08 Million | -1634.35% |
| 2013-02-28 | $135.61K | -90.78% |
| 2012-02-29 | $1.47 Million | +468.18% |
| 2008-02-29 | $258.84K | -- |
Equity Component Analysis
This analysis shows how different components contribute to MetaStat Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2938457900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (February 2018)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $588.00 | % |
| Other Components | $27.95 Million | % |
| Total Equity | $-1.55 Million | 100.00% |
MetaStat Inc Competitors by Market Cap
The table below lists competitors of MetaStat Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cambridge Nutritional Sciences plc
LSE:CNSL
|
$579.03 |
|
Scottish American Investment Co
LSE:SAIN
|
$579.86 |
|
Energy Finders Inc
PINK:EGYF
|
$580.80 |
|
GUANGZHOU R&F P-H-
MU:G5HA
|
$582.06 |
|
FieldPoint Petroleum Corporation
PINK:FPPP
|
$578.51 |
|
People’s Merchant Finance PLC
CM:PMBN0000
|
$577.78 |
|
YOMA STRATEGIC HLDG
BE:O3B
|
$577.71 |
|
Vanadi Coffee SA
MC:VANA
|
$577.51 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MetaStat Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2017 to 2018, total equity changed from -2,795,180 to -1,548,942, a change of 1,246,238.
- Net loss of 3,181,024 reduced equity.
- Share repurchases of 2,308,159 reduced equity.
- Other factors increased equity by 6,735,421.
Equity Change Factors (2017 to 2018)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.18 Million | -205.37% |
| Share Repurchases | $2.31 Million | -149.02% |
| Other Changes | $6.74 Million | +434.84% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares MetaStat Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-02-29 | $10.38 | $0.00 | x |
| 2009-02-28 | $-2.45 | $0.00 | x |
| 2010-02-28 | $-5.27 | $0.00 | x |
| 2011-02-28 | $-0.42 | $0.00 | x |
| 2012-02-29 | $1.36 | $0.00 | x |
| 2013-02-28 | $0.10 | $0.00 | x |
| 2014-02-28 | $-1.47 | $0.00 | x |
| 2015-02-28 | $0.15 | $0.00 | x |
| 2016-02-29 | $-0.97 | $0.00 | x |
| 2017-02-28 | $-0.94 | $0.00 | x |
| 2018-02-28 | $-0.29 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MetaStat Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -13652.46%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-487.57%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -44.56% | 0.00% | 0.00x | 1.69x | $-141.21K |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-370.78K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-75.87K |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-74.01K |
| 2012 | -165.00% | 0.00% | 0.00x | 1.20x | $-2.57 Million |
| 2013 | -1858.67% | 0.00% | 0.00x | 7.54x | $-2.53 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.16 Million |
| 2015 | -3295.06% | 0.00% | 0.00x | 4.54x | $-8.02 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.48 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.66 Million |
| 2018 | 0.00% | -13652.46% | 0.03x | 0.00x | $-3.03 Million |
Industry Comparison
This section compares MetaStat Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MetaStat Inc (MTST) | $-1.55 Million | -44.56% | N/A | $578.52 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |